MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma
about
MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma
description
im August 2018 veröffentlicher wissenschaftlicher Artikel
@de
scientific article published on 17 August 2018
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2018
@uk
name
MAP17 predicts sensitivity to ...... tezomib in lung adenocarcinoma
@en
MAP17 predicts sensitivity to ...... tezomib in lung adenocarcinoma
@nl
type
label
MAP17 predicts sensitivity to ...... tezomib in lung adenocarcinoma
@en
MAP17 predicts sensitivity to ...... tezomib in lung adenocarcinoma
@nl
prefLabel
MAP17 predicts sensitivity to ...... tezomib in lung adenocarcinoma
@en
MAP17 predicts sensitivity to ...... tezomib in lung adenocarcinoma
@nl
P2093
P2860
P1476
MAP17 predicts sensitivity to ...... tezomib in lung adenocarcinoma
@en
P2093
Irene Ferrer
Jose Manuel Garcia-Heredia
Luis Paz-Ares
Marco Perez
Rocío Suárez
Santiago Ponce-Aix
Álvaro Quintanal-Villalonga
P2860
P2888
P356
10.1186/S13046-018-0871-7
P407
P577
2018-08-17T00:00:00Z
P6179
1106156008